| Mantle cell lymphoma

Revlimid vs Tecartus

Side-by-side clinical, coverage, and cost comparison for mantle cell lymphoma.

Deep comparison between: Revlimid vs Tecartus with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTecartus has a higher rate of injection site reactions vs Revlimid based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tecartus but not Revlimid, including UnitedHealthcare

Category

Revlimid

Tecartus

At A Glance

RouteOral

FrequencyDaily on Days 1-21 of repeated 28-day cycles

ClassImmunomodulatory agent targeting cereblon

RouteIV infusion

FrequencySingle infusion

ClassCD19-directed CAR-T cell therapy

Indications

Multiple Myeloma
Myelodysplastic Syndrome with Isolated del(5q)
Mantle cell lymphoma
Lymphoma, Follicular
Marginal Zone B-Cell Lymphoma

Mantle cell lymphoma
Precursor B-cell lymphoblastic leukemia

Dosing

Multiple Myeloma (combination therapy) 25 mg orally once daily on Days 1-21 of repeated 28-day cycles, in combination with dexamethasone

Multiple Myeloma (maintenance therapy following auto-HSCT) 10 mg orally once daily continuously on Days 1-28 of repeated 28-day cycles

Myelodysplastic Syndrome with Isolated del(5q) 10 mg orally once daily

Mantle cell lymphoma 25 mg orally once daily on Days 1-21 of repeated 28-day cycles

Follicular Lymphoma 20 mg orally once daily on Days 1-21 of repeated 28-day cycles for up to 12 cycles, in combination with a rituximab-product

Marginal Zone B-Cell Lymphoma 20 mg orally once daily on Days 1-21 of repeated 28-day cycles for up to 12 cycles, in combination with a rituximab-product

Mantle cell lymphoma Single IV infusion at 2 x 10^6 CAR-positive viable T cells/kg (max 2 x 10^8 cells) following lymphodepleting chemotherapy with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on each of the fifth, fourth, and third day before infusion.

Precursor B-cell lymphoblastic leukemia Single IV infusion at 1 x 10^6 CAR-positive viable T cells/kg (max 1 x 10^8 cells) following lymphodepleting chemotherapy with fludarabine 25 mg/m2 IV on days -4, -3, and -2 and cyclophosphamide 900 mg/m2 IV on day -2 before infusion.

Contraindications

Pregnancy
Severe hypersensitivity to lenalidomide including angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis

—

Drug Interactions

1201View drug interactions

26View drug interactions

Adverse Reactions

Most common (>=20%) - Multiple Myeloma combination therapy Diarrhea, anemia, constipation, peripheral edema, neutropenia, fatigue, back pain, nausea, asthenia, insomnia

Most common (>=20%) - Multiple Myeloma maintenance therapy Neutropenia, thrombocytopenia, leukopenia, anemia, upper respiratory tract infection, bronchitis, diarrhea, rash, fatigue

Most common (>=20%) - Myelodysplastic Syndromes Thrombocytopenia, neutropenia, pruritus, rash, diarrhea, constipation, nausea, nasopharyngitis, cough, dyspnea, pharyngitis, epistaxis, fatigue, pyrexia, peripheral edema, asthenia, arthralgia, back pain, muscle cramp

Most common (>=20%) - Mantle Cell Lymphoma Neutropenia, thrombocytopenia, anemia, fatigue, diarrhea, nausea, cough, dyspnea, rash, pruritus

Most common (>=20%) - Follicular and Marginal Zone Lymphoma Neutropenia, fatigue, diarrhea, constipation, nausea, cough

Serious Venous thromboembolism, arterial thromboembolism, infections including pneumonia, second primary malignancies, hepatotoxicity, severe cutaneous reactions, tumor lysis syndrome, tumor flare reactions

Postmarketing Hypothyroidism, hyperthyroidism, hepatic failure, toxic hepatitis, angioedema, anaphylaxis, acute graft-versus-host disease, viral reactivation, progressive multifocal leukoencephalopathy, pneumonitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms

Most common (>=20%) - MCL CRS, fever, encephalopathy, hypotension, infection with pathogen unspecified, viral infections, fatigue, tachycardias, chills, hypoxia, tremor, cough, musculoskeletal pain, nausea, edema, headache, constipation, diarrhea, decreased appetite, dyspnea, rash, insomnia, pleural effusion, aphasia, motor dysfunction

Most common (>=20%) - ALL fever, CRS, hypotension, encephalopathy, tachycardia, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, vomiting

Serious encephalopathy, fever, infection with pathogen unspecified, CRS, hypoxia, aphasia, renal insufficiency, pleural effusion, respiratory failure, bacterial infections, dyspnea, fatigue, arrhythmia, tachycardia, viral infections

Postmarketing infusion related reaction; T cell malignancies (identified with BCMA- or CD19-directed genetically modified autologous T cell immunotherapies)

Pharmacology

Lenalidomide is an immunomodulatory agent that mediates cellular activities through binding to cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex, leading to degradation of substrate proteins and resulting in direct cytotoxic and immunomodulatory effects.

CD19-directed genetically modified autologous T cell immunotherapy; binding of anti-CD19 CAR T cells to CD19-expressing target cells activates CD28 and CD3-zeta co-stimulatory signaling cascades leading to T cell activation, proliferation, acquisition of effector functions, secretion of inflammatory cytokines and chemokines, and killing of CD19-expressing cancer and normal B cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Revlimid